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Plain English summary
Including patient and public involvement (PPI) in health research is thought to improve research but it is hard to
be clear exactly how it helps. This is because PPI takes many forms, is sometimes only token and is not always
reported clearly. This makes it difficult to combine the evidence so that clear conclusions can be reached about the
ingredients of successful PPI and what PPI achieves. Previous research that has tried to combine the evidence has
led to several guidelines for researchers to use in setting up and reporting PPI.
This paper was written jointly by researchers and PPI contributors as a reflection on our experiences. The aim was
to add to the evidence, by giving detail about the use of PPI in a large randomised controlled trial and the effect it
had. We were guided by published PPI reporting guidelines. The effects on the trial are shown in a table of
changes made because of suggestions from the PPI group. A survey was used to ask PPI contributors and
researchers about their experience and effects they had noticed. Three themes were noted: impact on the trial, the
effect of involvement on individual researchers and group members, and group environment. The PPI work
affected the trial in many ways, including changes to documents used in the trial and advice on qualitative data
collection methods and analysis. Individuals reported positive effects, including enjoying being in the group,
gaining confidence, and learning how to share views.
Abstract
Background: Patient and public involvement (PPI) is believed to enhance health care delivery research, and is
widely required in research proposals. Detailed, standardised reporting of PPI is needed so that strategies to
implement more than token PPI that achieves impact can be identified, properly evaluated and reproduced. Impact
includes effects on the research, PPI contributors and researchers. Using contributor and researcher perspectives
and drawing on published guidelines for reporting PPI, we aimed to reflect on our experience and contribute
evidence relevant to two important questions: ‘What difference does PPI make?’ and ‘What’s the best way to do it?’
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Methods: Fourteen people living with multiple long-term conditions (multimorbidity) were PPI contributors to a
randomised controlled trial to improve care for people with multimorbidity. Meetings took place approximately four
times a year throughout the trial, beginning at grant application stage. Meeting notes were recorded and a log of
PPI involvement was kept. At the end of the trial, seven PPI contributors and four researchers completed free-text
questionnaires about their experience of PPI involvement and their perception of PPI impact. The responses were
analysed thematically by two PPI contributors and one researcher. The PPI group proposed writing this report,
which was co-authored by three PPI contributors and two researchers.
Results: Meeting attendance averaged nine PPI contributors and three to four researchers. The involvement log
and meeting notes recorded a wide range of activities and impact including changes to participant documentation,
advice on qualitative data collection, contribution to data analysis and dissemination advice. Three themes were
identified from the questionnaires: impact on the study, including keeping the research grounded in patient
experience; impact on individuals, including learning from group diversity and feeling valued; and an environment
that facilitated participation. The size of the group influenced impact. Researchers and PPI contributors described a
rewarding interaction that benefitted them and the research.
Conclusions: PPI was wide-ranging and had impact on the trial, contributors and researchers. The group
environment facilitated involvement. Feedback and group interactions benefitted individuals. The insights gained
from this study will postitively influence the researchers’ and contributors’ future involvement with PPI.
Keywords: Patient public involvement, Qualitative, Randomised controlled trial,
Background
It is generally accepted that patient and public involve-
ment (PPI) enhances the value of health care delivery re-
search by making it more relevant to the targeted
patient group [1]. Consequently, PPI is now required in
all health care research undertaken for funders such as
the National Institute of Health Research (NIHR) in the
UK [2]. However, this may lead to tokenism [3–5] and
several reviews of PPI have concluded that evidence of
impact is weak [5–8]. A better evidence base is needed
to substantiate claims of benefit and to evaluate impact
and cost-effectiveness [9]. This would also facilitate
learning about how to achieve effective PPI and what
key factors operate when it does have impact [10–12].
Achieving a robust evidence base requires more com-
prehensive, structured reporting of PPI in individual stud-
ies [2, 3, 6, 13, 14]. Many suggestions have been made
about what should be included in planning and reporting
PPI [3, 5, 6, 12–19] and some detailed tools have recently
become available [12, 17, 20]. Some argue that the com-
plexity of PPI makes it difficult to assess its impact on re-
search beyond documenting contributions [21]. Others
have noted that the impact on individuals, both contribu-
tors and researchers, should not be overlooked [13]. At-
tempts have been made to categorise PPI activity to aid
reporting [14] and to design a structured set of questions
to plan and prompt reflection on PPI [18]. Some consen-
sus has developed about what leads to successful PPI in a
research study, including planning how to incorporate
PPI, initiating PPI from the outset and good relationships
between researchers and PPI contributors [3, 7, 14, 15].
Reports of PPI should include contextual details, because
the mechanisms for successful PPI will vary with the type
of study, PPI aims, resources available and what values are
held by researchers, particularly the Chief Investigator,
regarding PPI [3, 5, 8, 10, 13].
This paper describes the PPI processes within a rando-
mised controlled trial (RCT) setting and analyses the
perceptions of both PPI contributors and researchers re-
garding the process and impact of the PPI and the chal-
lenges they experienced. This addresses a relative gap in
the literature as reports of PPI from both researcher and
contributor prespectives are under-represented, as are
reports of PPI in RCTs [15]. Following Crocker [21] and
Dudley [15], we have used the term ‘PPI contributor’ to
refer to the members of the PPI group, as they were not
co-applicants in the research proposal or co-researchers
in carrying out the research. Instead they were consulted
and actively contributed their ideas to help shape how
the research was carried out.
The paper was initiated by the PPI group towards the
end of the trial, who wished to record their contribution
to the trial and their experience. We aimed to create a PPI
report that included recommended detail on context,
process and impact to add to the evidence base and which
would facilitate evidence synthesis by conforming to pub-
lished reporting guidelines as far as possible [3, 12, 13, 17,
20]. Thus, the main aim of this paper is to contribute evi-
dence towards understanding how and in what circum-
stances PPI makes a difference. We also aimed to provide
an example of how researchers and contributors with little
experience of PPI succeeded in overcoming tokenism,
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achieved meaningful collaboration and experienced indi-
vidual impact. We hope that this will be encouraging and
informative to other researchers in a similar position.
Description of trial
The PPI group contributed to a large cluster RCT (The
3D Study; ISRCTN06180958) that took place in 33 gen-
eral practices in three areas of the UK. The aim of the
RCT was to improve the care of people with a wide
range of multiple long-term conditions (multimorbidity)
by addressing patient-reported generic deficiencies in
their care and issues that negatively impacted their qual-
ity of life [22]. The intervention aimed to enhance con-
tinuity of care and establish a more patient-centred
approach to reviewing patients with multimorbidity by
eliciting patients’ own agendas, reviewing all conditions
together and agreeing shared action plans to address is-
sues. Full details are available in the protocol paper [22].
The trial design included an economic evaluation to
examine cost-effectiveness and a process evaluation [23]
to explore participants’ response and how and why the
intervention was implemented or not. The intervention
ran over 15 months and involved 1546 patients, 797 of
whom were in the 16 intervention group practices. The
trial funding began in March 2014 and concluded in
September 2017. The funding proposal took over a year
to develop prior to the start of the trial and included PPI
funding of £13,612 plus 5% FTE of one researcher to co-
ordinate the PPI, representing approx. 1.1% of the total
cost.
Aim of PPI
The aim of the PPI was to ensure maximum relevance
of the trial intervention to people with multimorbidity,
to enhance response to recruitment and follow-up, to
help interpret results and to gain assistance with dissem-
ination to interested groups and individuals. Plans for
PPI described in the proposal specified meeting 4 times
a year to advise on patient information leaflets, question-
naire design, ethical issues, recruitment approaches, dis-
semination of results, and impact. We also stated the
intention to identify two members of the group willing
to sit on the Trial Steering Committee and the Trial Ad-
visory Group and another member to contribute to the
qualitative data analysis. The PPI group was named the
Patient Involvement in Primary Care Research (PIP-
CaRe) group to give it an identity and to reflect a wider
aim of it being a resource that researchers developing
new primary care research ideas could use.
Methods
During proposal development, PPI co-ordination and fa-
cilitation was delegated to a named co-applicant (CM).
An open meeting to discuss the research proposal was
advertised with relevant patient groups and local PPI fa-
cilitators. Four people responded to the first invitation.
There were no formal selection procedures beyond the
criterion of living with multimorbidity as a patient or
carer. Recruitment continued until, in December 2013
just prior to the start of the research programme, an
introductory meeting was set up with fourteen PPI con-
tributors. Two had prior experience of PPI and two were
co-ordinators of voluntary patient groups. The PPI co-
ordinator had minimal previous exposure to PPI and no
previous experience of facilitating PPI groups but had
prior training in group facilitation. After becoming co-
ordinator she attended two one-day courses on PPI in
research that drew attention to important facilitation
considerations such as the group’s needs and different
motivations.
Eleven PPI contributors remained in the PIP-CaRe
group after a year, of whom 3 were male. The age range
was approximately 45–85 and contributors had a variety
of long-term conditions. They all continued to attend
meetings throughout the trial, averaging nine PPI con-
tributors at every meeting. Following the introductory
meeting, the group met four times in 2014, three times
in 2015, and four times in 2016 and 2017. Between
meetings, PIP-CaRe members were often asked for their
opinions by email. They were compensated for their
time at the rate of £12 per hour for meetings, prepar-
ation work, and for additional work or reading under-
taken between meetings. These payments were made in
vouchers and payments for travel expenses were in cash.
Meetings were board-room style on university premises
with lunch provided. Diet, mobility, sight and hearing
needs were accommodated where possible with alterna-
tive food options, access on the level or by lift, large font
for meeting papers and rooms with good acoustics. Two
other members of the lead site research team also
attended meetings regularly; the trial manager (MM)
and the main trial researcher. The Chief Investigator of
the trial was supportive of PPI and attended approxi-
mately one third of meetings. Occasionally other re-
searchers attended for a specific purpose, such as
development of a new patient-reported measure used in
the trial. In the first year, the PPI co-ordinator provided
half a day’s training in trial methodology to PIP-CaRe
members. They were also encouraged to attend free
training at a local PPI hub. Nine members attended the
trial methods training and five attended the local PPI
training. One year into the trial, one member left the
group following unresolved conflict with the PPI co-
ordinator when differing participation requirements
within the group became incompatible. Following this,
the functioning of PIP-CaRe was appraised and members
were asked by questionnaire about their needs in attend-
ing the group. This resulted in some adjustments to the
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physical environment. The group discussed whether they
were happy with how PIP-CaRe was chaired and facili-
tated and chose not to make any changes.
Data
Throughout the trial, a log was kept of all PPI activity
and contributions. Detailed notes of PIP-CaRe meetings
were written up by the PPI co-ordinator immediately
after the meeting and circulated to all attending re-
searchers to check accuracy. Within a week of the meet-
ing, the notes were sent to the whole group, who were
also asked to amend anything they felt to be inaccurate.
Those who had not attended were also sent a copy so
that they remained informed.
Towards the end of the 3D Study both PPI contribu-
tors and researchers were invited to comment on their
experience of working with the PPI group. A question-
naire, developed with input from PIP-CaRe, was provided
to group members and to researchers. The purpose was to
prompt reflection on both process and impact and enable
all involved to relate their experiences in general terms,
whilst providing specific examples where they wished.
Both questionnaires are shown in Table 1. The PPI co-
ordinator did not complete the questionnaire but her re-
flections are included in the discussion.
Analysis
The meeting notes were scrutinised for examples of impact
and used to check the accuracy of the activity log. The ques-
tionnaire answers were first collated question by question
into PPI contributor responses and researcher responses and
drafted into a narrative by two PPI contributors (SC and
KP). The narrative was then discussed in the whole group
who made some additional points, particularly about the PPI
perspective on quality of life. The collated comments were
thematically analysed using codes that arose from the data.
The codes were grouped into themes which were agreed
between CM, SC and KP.
Results
First, we present the PPI activities and demonstrable im-
pact based on the meeting notes and activity log that
were kept throughout the trial, followed by the findings
from the questionnaires addressing perceptions of PPI
contributors and researchers.
The activities the PPI contributors were involved in
were very wide-ranging and included all those specified
in the funding proposal as well as others. The main ac-
tivities that had impact on the trial conduct are shown
in Table 2. A full list appears in Appendix 1.
Seven PPI contributors and four researchers completed
the questionnaires. The findings are grouped into research
impact, personal impact and environment. In attributing
quotes, researchers are designated by the numbers R1–4
and PPI contributors by the numbers P1–7.
Research impact
PPI contributors and researchers agreed that PPI contrib-
utors had played an essential role in the 3D Study. They
had bridged the divide between the academic and “real
world” by presenting their real-life experiences to provide
researchers with a “sounding board” and a “reality check”.
They could maintain focus on how participants might be
Table 1 PPI contributor and researcher questionnaires
PPI contributor questions Researcher questions
Why do you think it is important that the group was involved? Why do/did you think it is important that the group was involved?
What do/did you see as the group’s purpose in the study?
What do you think has been the most important contribution made by:
a. The group?
b. By you?
What do you think has been the most important contribution
made by the group?
What other contributions have been made? In your opinion, what other contributions have been made?
What has given you the greatest satisfaction in working with the 3D study? What has given you the greatest satisfaction in working with the group?
What barriers and facilitators have there been to you taking part
in the PIP-CaRe group?
What (if anything) has been difficult or challenging in working
with the group?
a. For the trial?
b. Personally?
Where have you experienced unexpected benefits from working
with the group?
a. For the trial?
b. Personally?
What lessons do you think could be learned from the experience?
a. Personally?
b. By researchers?
What lessons do you think could be learned from the experience?
a. Personally?
b. By researchers in general?
Anything else you would like to add? Anything else you would like to add?
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Table 2 PPI activity log
Activity Demonstrable impact
Considered the research proposal and its relevance to the
priorities of the targeted group of patients
Could state in the funding proposal that the intervention addressed the
priorities of patients with multimorbidity.
Commented on study design and advised on consent
procedure and patient response
After the pilot study, the trial management group decided that a specific
decline form would not be included in the invitation pack for the trial.
However, the PPI group felt that there should still be a means to actively
decline so that patients were not sent reminders. We agreed that
participants could return a blank questionnaire as a means of declining and
changed the invitation letters accordingly. Only those who did not send
any response to the invitation were reminded.
The group later highlighted concerns that patients might have about their
questionnaire responses being seen by their health care team. As a result,
a statement was added to the front page of follow-up questionnaires that
patients’ answers would not be shared with their surgery
Gave feedback on recruitment documents for patients including
information sheets, consent forms and invitation letters to
patients
Information sheets were changed from a two-column format to one and
the language was simplified and clarified.
Gave feedback on patient questionnaires Changes made to the formatting to make them easier to read for
partially-sighted people and the layout clearer. Changes to the first page
to emphasise appreciation of patients taking time to complete them.
Some things they would have liked to change, e.g. wording of questions,
were not possible due to the use of validated measures.
Contributed to developing a new measure of treatment burden The questions in the measure were shaped by PPI contributors’ responses
to an existing measure and the new measure was tested on them and
refined before being piloted
Took part in a pilot focus group to help develop the focus group
schedule for patients participating in the process evaluation
The order of the focus group schedule was changed following feedback
to make it flow better and the questions were made more open.
Contributed to development of training for clinicians taking
part in the trial
Provided comments on their care and what was important to them in
receiving care for multimorbidity to use as quotes in the training slides.
One PPI contributor was video-recorded in a role play consultation with
the CI for use in training. However, this was not eventually included.
Emphasised the need for the training to put the patient’s perspective
more strongly which was reflected in revisions to the training made
following the pilot phase.
Advised on content and format of the study webpage and
contributed to content
Wording was changed from managing patients with multimorbidity to
treating patients with multimorbidity. A picture was changed to show a
female GP with a male patient. Suggestions for links to other resources
were incorporated. A video was recorded of several PPI contributors
discussing the 3D study of which an extract was uploaded to the website.
Advising on qualitative interview schedules and on what to look
for in observation of consultations that would indicate
patient-centredness
from their perspective
The interview schedules and observation checklists were revised to
incorporate their comments
Two PPI contributors assisted with qualitative data analysis as
second coders and the group commented on selected transcripts
and recordings
The PPI contributors coding affirmed that of the process evaluation researcher
and the PPI group’s comments helped with judging the patient-centredness of
recorded intervention consultations
Providing feedback on a planned conference presentation Changes were made to the presentation that reflected PPI contributor
comments and made it easier to follow by changing the order of the slides
Advised on content and format of the patient newsletter Suggestions regarding pictures and content were incorporated e.g.
changing the wording from management to treating and the text in
the dark boxes was changed to a colour better for visually impaired people
Dissemination The group suggested means of disseminating to community and patient
groups that were incorporated into the dissemination plan
Publishing their experience of PPI in the 3D study Several PPI contributors initiated the idea of writing a paper on the PPI in
the 3D study which has led to this paper. Three of them (SC, KP, EB) have
been actively involved in drafting it.
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experiencing the intervention and provide insight into
their likely responses.
“It was vital that you had a group of people who could
give you a wide cross section of views and experiences on
how we have been treated with regard to multiple health
issues in the real world …. to keep you grounded.” [P4]
The group was needed “to provide feedback and
‘reality-testing’ on our ideas, plans and research tools;
to contribute a range of different perspectives.” [R2]
Nevertheless, one PIP-CaRe member perceived that
the research team was sometimes insufficiently sensitive
to patients’ perspectives.
“on occasion researchers paid not enough respect to
the ‘subjects’ selected for the research…I sometimes felt
that the subjects were taken for granted.” [P2]
Many PPI contributors highlighted their contribution
in making written materials more accessible to the re-
cruited patients.
“We have achieved paperwork that makes sense to
people and is useful to them.” [P3]
But, one researcher, who was developing a new measure
for use in the trial, thought high levels of literacy within the
PIP-CaRe group, when compared with the general popula-
tion, may have reduced the generalisability of their advice.
“In terms of developing the questionnaire, with
hindsight it may have been more appropriate to
conduct the cognitive interviews with patients who
were more similar to patients taking part in the
main trial and to the general population …
members of the PIP-CaRe group tended to have
high levels of literacy.” [R1].
Group members claimed they had influenced how data
were collected and interpreted.
“We have suggested reasons why different things like the
death-rate in the project might have happened.” [P3]
Their experiences of dealing with social support net-
works and the wider community were also useful.
“I think that the unexpected benefits have come from
finding out about other organisations and groups that
the members have been involved in. Some of the group
are very active in community projects and have
connections with local organisations.” [R3]
Researchers commented on the genuine interest and
engagement from PIP-CaRe members that led to mean-
ingful discussion and challenge. One researcher con-
cluded that the size and mix of the PPI group enabled
them to challenge, leading to greater impact in an envir-
onment where people could be heard.
“The PIP-CaRe group have the confidence to be
challenging, to ask difficult questions of the research
team…. because it is a larger group, which has some
strong personalities and this gives it more confidence
and clout than just having two PPI reps on the project
group.” [R2]
Group members perceived that their ideas and opin-
ions had a direct and positive impact on the research.
“I’m sure the researchers have been challenged and
occasionally surprised by the opinions of the group.” [P1]
Both researchers and PPI contributors valued the
group’s diverse experience and recognised that everyone
had something to contribute and should be listened to
even when opinions differed.
“…all the PIP-CaRe group make different sorts of con-
tributions, at different levels and in different ways. So
there is no best way to do it, we just need to listen to
everyone and hear what they are saying.” [P5]
“I believe that the PIP-CaRe group contains a varied
group of people with diverse backgrounds, opinions
and life experiences. We have not always agreed with
one another, but we have always been encouraged to
speak and we’ve been heard.” [P1]
Sometimes researchers struggled with the group’s lack
of understanding and/or acceptance of the boundaries
and constraints of the research and one researcher felt
frustrated when she could not incorporate a good idea
because of those constraints
“I found it frustrating and felt it a weakness on
my part that we couldn’t make all the changes
the group suggested e.g. changing validated
questionnaires.” [R3]
Personal impact
Both researchers and contributors found that communi-
cation could be complicated by the diversity of the
group. However, it could lead to individual learning.
One researcher had learnt to take time to understand
what PPI contributors were saying and to communicate
more clearly herself.
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“I think that I have learned to have more patience to
allow PPI members time to explain themselves. I
think I have also had to learn how to explain myself
clearly.” [R3]
Several PPI contributors realised the importance of
listening to others and understanding the different ways
in which they expressed themselves.
“I need to be a better listener. I am used to meetings
…… where the participants are used to focus clarity,
external constraints and the need to quickly reach a
resolution. I had to step back from that environment
and listen to people who expressed their views in a
more indirect and personal way.” [P6]
When asked about their experience of being in the
group, PPI contributors described being involved, enthu-
siastic, listened to and valued. The benefits and enjoy-
ment of working with other group members who
brought different experiences and ideas to the discussion
could be personally enriching.
“I thoroughly enjoyed contributing to the group and
the ideas that drove the project forward.” [P6]
“Personally I feel I have gained experience of medical
conditions. I have enjoyed meeting other members, and
hearing the views of others.” [P2]
Many placed personal interactions with researchers
and PPI contributors among the most satisfying and en-
joyable aspects of working on the study. Researchers
gained from what the PPI contributors were willing to
share about their lives and PPI contributors stated they
had gained knowledge about research.
“I have particularly enjoyed learning about the process
involved in carrying out a research project, and the
interactions with the research team and the other
members of the PIP-CaRe group.” [P1]
“[It has given me] greater understanding of the
patients involved in the trial and all the other
factors that impact their lives daily yet most
remain so positive (both PPI and trial patients)!”
[R4]
The genuine engagement of the the PPI contributors
made the research seem worthwhile and was very re-
warding for researchers
“The greatest satisfaction has been developing a
rapport and relationship with individuals and the
group. It reminds me that the ultimate aim is to help
patients’ wellbeing.” [R3]
“Seeing how much they have bought into the trial and
how much they view it as theirs – with pride.” [R4]
From the perspective of the PPI contributors, the sense
that they had the ability to make a difference was the main
source of satisfaction
“Seeing suggestions or comments I have made used
and that you have seen what I have to say as useful to
others.” [P4]
There was also some evidence that PPI contributors had
gained confidence as a consequence of their involvement.
“I feel I have gained more confidence in meeting
members of the medical profession- might find
discussion with them easier.” [P2]
“I think I have had the knowledge that it is not neces-
sary to have higher education to be able to speak coher-
ently and cogently, reinforced.” [P3]
Environment
The group appreciated the researchers’ efforts in trying
to meet PPI contributors’ needs regarding travel, timing
of meetings, room access, diet, sight and hearing. How-
ever, some PPI contributors experienced difficulties at-
tending meetings due to illness, treatment demands,
employment or other commitments.
PPI contributors were unaware of any barriers to par-
ticipation and most comments emphasised the experi-
ence in a positive light. Overall, the group seemed able
to talk freely, and equally and were receptive to the
views of others.
“I did not feel there were any barriers to participation,
which was always welcomed by the researchers.” [P2]
Discussion
The process that influenced PPI contributors’ impact
on the trial included appointing a designated co-
ordinator, inclusive recruitment to the PPI group,
training, explanation of trial methodology and terms,
role clarification and development, good communica-
tion within and outside meetings, negotiation, conflict
resolution, feedback on PPI contributors’ suggestions,
and support and involvement from the Chief Investi-
gator and other researchers. Material elements
included having a suitable place to meet and adequate
funding. All these factors support successful PPI
[7, 10, 14, 15, 20, 21, 24].
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Our PPI process was broadly consistent with previous
recommendations about PPI implementation [10, 24], al-
though only the INVOLVE guidelines were consulted at
the trial outset. Our appraisal covers many of the questions
raised in the PiiAF framework [17] and maps well to the
standard operating procedure (SOP) developed by Evans et
al. [20] in timeframe, planning, resourcing, PPI co-
ordinator role, support from the Chief Investigator and
involvement of the PPI group at all stages of the trial. Our
experience also aligns with the findings of the RAPPORT
study [7], which identifies six conditions most influential in
establishing effective PPI. Four of these were evident in our
study: a research team positive about PPI, a key individual
to co-ordinate, ensuring diversity, and relationships that are
established and maintained over time. The other two condi-
tions, a shared understanding of moral and methodological
purposes of PPI and proactive and systematic evaluation of
PPI were at least partially met in our work.
In line with recommendations, we have reported on all
aspects of the PPI process we undertook, largely comply-
ing with the reporting recommendations in GRIPP2 [12].
The GRIPP2 short form was insufficient for our purposes
but our report does not entirely comply with the GRIPP2
longform either, since it was a retrospective appraisal and
was not conceived as a research study of PPI in its own
right. Therefore, we have not explicitly used either, al-
though much of what we report maps to those checklists.
Our findings echo others’ experience that building
good relationships can be challenging, requiring flexibil-
ity, clarity of expectations, and skilful facilitation [10,
25]. The incidence of significant conflict that led to one
PPI contributor leaving the group highlighted the im-
portance of clarifying needs and expectations at the out-
set. If this had been done, a compromise might have
been negotiated that reconciled the different require-
ments individuals had to be able to participate.
Initially, the PPI co-ordinator felt there was an academic
divide, with researchers sometimes seeming to defend
against the PPI contributors’ comments, although this was
a perception not necessarily shared by the PPI contribu-
tors. Tension can occur over who has control of the re-
search [5, 25] and in this case may have resulted from a
perception that PPI contributors wanted more influence
over the research than researchers felt they could give.
Later, slight tension arose because some members of the
PPI group were interested in the impact of the interven-
tion on individuals’ behaviour, whereas the trial design
only allowed for generalisable results. Some members of
the group would have liked more say in which outcomes
were measured, and were frustrated in this by not being
involved until the trial was fully designed. However, they
did significantly contribute to development of a measure
of treatment burden that was used in the trial. Ultimately,
contributors’ wish to know more about intervention
impact on individual patients was largely satisfied by shar-
ing and inviting comment on anonymised data from the
process evaluation. These qualitative data explored partici-
pants’ perceptions of the intervention.
Researchers had their own perception of what they
wanted from the PPI group, which did not necessarily coin-
cide with PPI contributors’ interests [18]. Another possible
factor was that PPI contributors had divergent expectations
and motivations that differed depending partly on the
amount of PPI experience they had [14, 15, 24, 25]. How-
ever, the PPI co-ordinator perceived that as the relation-
ships between the researchers and the PPI contributors
evolved, mutual trust deepened, which was evident in in-
creased openness in communication. Researchers seemed
to relax and perceive greater potential for the PPI group to
contribute to the trial. PPI contributors seemed to gain
confidence and freedom to challenge which led to an en-
hanced sense of making a difference and a strong sense of
ownership towards the trial [14, 15, 24].
Ultimately, both PPI contributors and researchers experi-
enced personal benefits and satisfaction from their involve-
ment and felt that challenge and difference produced
constructive outcomes. PPI contributors engaged well with
the research process and found the technical, clinical and
procedural aspects of it interesting. The Chief Investigator,
although already supportive of PPI, had not previously ex-
perienced such a high level of engagement, perhaps leading
to revised expectations of PPI in future research [5]. Al-
though there were some tensions, the expectations of re-
searchers and PPI contributors regarding the research were
sufficiently aligned to avoid the situation of ‘colliding
worlds’ [5, 25]. The research team’s regular feedback on the
impact of PPI contributors’ input was noted and valued,
helping to maintain motivation and engagement [3, 15, 21].
Since the relationships that develop between researchers
and PPI contributors are pivotal to the success of PPI [13,
24], the quality of the relationships may perhaps be used
as an additional indicator of success, alongside the impact
on the trial and those taking part. In line with other re-
search, one PPI contributor suggested that the designated
coordinator was key to constructive interaction [10, 24].
The co-ordinator should be experienced in the potential
challenges of PPI, including power and control issues, and
the consequences of PPI contributors lacking knowledge
of research processes, terminology, and ethical constraints.
In addition, the PPI co-ordinator should be sufficiently
aware of the needs of the PPI group itself.
Despite some challenges, the diversity of PIP-CaRe
group members was clearly perceived to be a strength in
our study, because of their range of experience. This in-
cluded prior research experience as there were both
research-naïve and experienced PPI contributors in the
group [10, 26]. Although the research-naïve contributors
sometimes required lengthy explanations and made
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suggestions incompatible with research design and ethics
constraints, they also asked thought-provoking ques-
tions. They used their own experience to provide a very
real patient perspective, reminding researchers of the
potential real-life impact of the research [15]. Experi-
enced contributors, with greater understanding of re-
search, seemed more confident to comment about and
challenge the research design. These observations are
reflected in the debate about whether previous PPI ex-
perience is desirable [10, 26] and linked to the question
about the extent to which PPI contributors should be
representative of the population on which the research
is being carried out [4]. It is usually not feasible to
achieve representativeness in PPI recruitment which re-
lies on people volunteering [4]. Some may feel this is a
flaw in PPI work, as did one researcher in our study with
respect to literacy, but contributors may need to possess
different characteristics from research partipicants, such
as a certain level of literacy so that they can contribute.
However, PPI contributors and research participants do
need to share some characteristics, principally personal
experience of the condition being researched.
Another strength of this study is that we have included
diverse evidence of impact. The activity log provides evi-
dence for impact on the trial, and the researchers’ and PPI
contributors’ perspectives demonstrate impact on the ex-
periential knowledge of both; knowledge that is gained
through the interaction of individuals [13, 27]. However,
whether the impacts on the trial translated into a difference
in trial outcomes by influencing intervention implementa-
tion is not possible to determine. The group strongly sup-
ported early involvement and felt they might have had
more impact if they could have contributed more to the ac-
tual research design including outcome measures, which
echoes recommendations made by others [14, 15]. Al-
though two PPI contributors sat on the trial steering com-
mittee and advisory group, the sense of co-ownership of
the research and impact might have been strengthened if
there had been a co-applicant from the target patient group
involved from the very beginning of the trial design.
Conclusion
Our PPI was wide-ranging, contributed to every stage of
the trial and demonstrably had impact on trial processes.
Both researchers and PPI contributors had a positive ex-
perience which will influence future PPI involvement.
From this, we conclude that the PPI was successful. In
fully reporting the PPI in the 3D study we have contrib-
uted to the evidence base regarding both ‘What differ-
ence does PPI make?’ and ‘What’s the best way to do it?’.
This detailed study report may thereby help others to
maximise their PPI group potential to contribute to and
co-own the research and provides a useful addition to
the published evidence of PPI in research.
Appendix 1
PPI input log
Meetings every 3 months attended by average 10 people
each time.




Confirmed relevance of intervention to their
concerns. Strengthened emphasis on
co-ordination of care
Dec 2013 Agreed on acceptable terms to be used:
‘Several long lasting health problems’ instead
of co-morbid or multimorbidity
‘Patient’ and ‘intervention’ were acceptable
‘New approach’ also acceptable so long as
not abbreviated to NA
Jan/March 2014 Insisted that patients lacking capacity to consent
and carers should also be included in study.
March 2014 Voted on study logo design and strapline for trial
March 2014 Highlighted the importance of confidentiality
of patient health data, particularly in the use
of an external software company.
June–Sept 2014 Advised on formatting and wording of patient
questionnaire and instigated changes to list of
conditions and some wording.
Additional introductory sentences were added
on the front page of the questionnaire to
express appreciation of participants’ contribution
in completing it. A comments box was deemed
necessary.
June 2014 Advised on formatting (1 column instead of
multiple newpaper style columns) and wording
of patient information sheet and invitation letter.
Emphasised need for large fonts sizes and
alternative formats for those with impaired vision.
June 2014 Advised on how to help the process of booking
longer appointments. Suggested words or scripts
for receptionist. Members volunteered to help
role-play such scripts.Advised on wording of the
3D card to state ‘My usual GP is:…
’ instead of ‘Your usual GP is…’
July–Aug 2014 9 members interviewed for development of new
treatment burden questionnaire. 3 Carers were
also interviewed to help the development of a
treatment burden for carers questionnaire.
Helped test and validate resultant questionnaires.
Sept 2014 Drew attention to potential concerns that
participants might have about questionnaire
results being made known to GP practices
Sept 2014 Further feedback on patient questionnaires:
Suggested including the length of
time required to complete questionnaire
Highlighting where questions asked about their
GP practice, that answers were confidential and
would not affect the care they receive.
Suggested other examples of social activities
Queried the use of the word ‘Chronic’ – changed
to ‘Long term’.Ways to improve formatting to
help visually impaired eg spacing of boxes and
shading to break up sections.
Sept 2014 5 members took part in focus group about
usual care
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(Continued)
Timing Contribution
6 Oct 2014 2 members attended Trial Steering Committee
Dec 2014 Helped with test-retest reliability of treatment
burden questionnaire
5 Jan 2015 1 PPI representative attended the study
Advisory group meeting
Mar 2015 Advised on revised patient information
documents following pilot study.
Group felt strongly that patients who did not
want to take part must be given a way to say
so to prevent further contact otherwise it may
be seen as harassment. This suggested need for
active decline if removing the decline form
Suggested including a statement that patients
were involved the design of the trial, to try to
improve recruitment rates.
Mar 2015 1 member volunteered to help with analysis
of qualitative patient data
23 March 2015 1 PPI representative attended the Trial Steering
Committee
June 2015 PPI group had been asked general questions
about how their conditions affect their life,
what is difficult, what would help etc. Quotes
were extracted to highlight the problems
patients faced, to be used in the practice
training sessions
June 2015 One PPI member volunteered to be video
recorded in a mock consultation of a 3D nurse
and GP review. This had been at the suggestion
of the PPI representative on the TSC, and agreed
amongst trainers and practice staff would be a
useful resource.
Aug2015 1 member joined the CAPC steering group for
PPI&E
29 Sept 2015 2 PPI representatives attended the Trial
Steering Committee meeting
Oct 2015 Group provided suggestions about what CM
should be asking in the interviews and focus
groups with patients.
Oct 2015 Group also gave suggestions about what to
look for in observing consultation reviews as
evidence of patient-centredness. Eg. appropriate
eye contact, opening and closing of review, open
or closed questions, did their approach adapt
to different patients?
22 Oct 2015 2 PPI representatives attended the study
Advisory group meeting
Dec 2015 Group reviewed a Patient letter explaining the
change in follow-up questionnaire timing (from
6 and 12 months, to 9 and 15 months). Wording
clarified prior to submission as part of ethics
amendment 10.
Feb 2016 The group reviewed the first patient newsletter.
Those with visual impairments stressed the
importance of text size and also where the
contrast of text on coloured boxes made it
difficult to read. Yellow text on dark blue
background was preferred.
Feb 2016 Group reviewed the study website. Did not like
the use of the word ‘managed’ and suggested
replacing the main image with a photo of a
(Continued)
Timing Contribution
female doctor with patient. Also suggested
changes to headings, clarifying some words and
definitions, highlighting where information
needed updating, where navigation links were
broken and PPI pages needed to be made more
prominent.
Feb 2016 Total of 6 members took part in 2 focus groups
to discuss opinions and experiences of medication
reviews. This was to help shape a new sub-project
about pharmacy reviews (led by PD).
April 2016 5 members offered to help with a goal setting
project proposal led by CM.
May 2016 Group posed for photos to be used on the
PPI pages of the study websiteFurther feedback
on study website. Suggested links to other
helpful or relevant websites (listed as Other
Resources).
May 2016 Identified 2 members to assisting with analysis
(checking coding and developing themes)
of qualitative patient data
Sept 2016 5 members were video recorded having a
discussion about the importance of the 3D
study and why they got involved. Extract to
be made publically available on the study
website.
26 Sept 2016 1 member attended the Trial Steering Committee
Oct 2016 Group feedback on audio excerpts from GP
consultations. Opinions and comments used
to corroborate examples of good and poor
patient centred care.
Oct 2016 Review of second patient newsletter.
Photo from the group discussion (Sept 2016)
used on the newsletter.
Jan 2017 Group discussion of patient focus group
transcripts and patient case study to explore
views of experiences and help to validate
interpretation of qualitative data.
Jan 2017 Discussion of study dissemination plan.
Suggested local and national organisations,
charities and media that could be approached
to disseminate study results.
Jan – March 2017 Several members expressed an interest in
writing a research paper about their contribution
of being part of a PPI group involved in research.
7 members provided personal views to key
questions. 2 members collated and wrote a draft
of emerging themes.
April 2017 Fed back on draft of paper about PPI experiences.
Discussions of different motivations and
acknowledging that patients, researchers and
health care professionals all have different
perspectives.Expressed an interest to submit an
abstract to the Involve conference.
April 2017 Provided suggestions on what information
would be of interest to patients at the end
of the study (for study patient newsletter).
28th April 2017 Abstract submitted for INVOLVE conference
May 2017 Abstract accepted for poster presentation at
INVOLVE conference
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(Continued)
Timing Contribution
June 2017 Results section of PPI in research paper written.
Starting to develop discussion section of paper.
26 June 2017 Fed back on CM’s HSRUK conference
presentation on the effect of the 3D template
on patient centredness.
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